Research Report University Hospital of the clinical trial CC-5013-MCL-002

Abstract

A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid(R)) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Keywords

• Mantle Cell Lymphoma
• Lenalidomide (Revlimid)